A multicenter, randomized, placebo-controlled, double-masked, parallel-group study was
performed to compare the efficacy and safety of valsartan 20, 80, 160, and 320 mg with …

Background: Losartan, the first of the angiotensin II receptor blockers (ARBs) to be
introduced, has been studied extensively in comparison with other classes of …

Objective: To compare the antihypertensive efficacy and systemic tolerability of valsartan, a
new angiotensin II receptor antagonist, with placebo and with an angiotensin converting …

Objective: To study the efficacy and tolerability of a range of valsartan doses in patients with
mild-to-moderate hypertension. Design: 122 adult out-patients were randomised in equal …

Objective: To compare the efficacy, safety and tolerability of valsartan to an angiotensin-
converting enzyme (ACE) inhibitor, lisinopril, and placebo in patients with mild-to-moderate …

Objective: To compare the antihypertensive efficacy of a new angiotensin II antagonist,
valsartan, with a reference therapy, hydrochlorothiazide (HCTZ). Methods: In this double …

We compared the angiotensin II receptor antagonist valsartan to losartan as an
antihypertensive agent in an 8-week trial. Adults with uncomplicated essential hypertension …

Synopsis Valsartan competitively and selectively inhibits the actions of angiotensin II at the
AT 1 receptor subtype which is responsible for most of the known effects of angiotensin II. In …

Objective: This study compares the antihypertensive efficacy and tolerability of valsartan, a
novel angiotensin II antagonist, given with hydrochlorothiazide (HCTZ) vs placebo or vs …

This study was done to assess the antihypertensive efficacy of once-daily valsartan 20 mg,
80 mg, 160 mg, and 320 mg over 24 hours using ambulatory blood pressure monitoring …